Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide in Pediatric Participants With Type 2 Diabetes Mellitus
NCT06739122Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Events Considered Related to Study Drug at 26 weeks. Started Jan 2025; status: recruiting.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06739122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06739122.